ALT
Altimmune, Inc.
Key Financials
Net Income
$-88093000
↑ 7.3%
Total Assets
$279.9M
↑ 100.9%
EPS (Diluted)
$-1.00
↑ 25.4%
Shareholders' Equity
$224.9M
↑ 82.1%
Total Liabilities
$55.0M
↑ 248.4%
Cash & Equivalents
$43.8M
↑ 18.5%
Long-term Debt
$34.3M
↑ 5886.2%
Operating Cash Flow
$-67535000.00
↑ 15.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 4/16/2026 | View on SEC |
| 4 | 4/6/2026 | View on SEC |
| 4 | 4/1/2026 | View on SEC |
| 4 | 4/1/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| ARS | 3/17/2026 | View on SEC |
| DEF 14A | 3/17/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
| PRE 14A | 3/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALT |
| Company Name | Altimmune, Inc. |
| CIK | 1326190 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 2406541450 |